PL3322724T3 - Inhibitory IL-26 - Google Patents

Inhibitory IL-26

Info

Publication number
PL3322724T3
PL3322724T3 PL16739098T PL16739098T PL3322724T3 PL 3322724 T3 PL3322724 T3 PL 3322724T3 PL 16739098 T PL16739098 T PL 16739098T PL 16739098 T PL16739098 T PL 16739098T PL 3322724 T3 PL3322724 T3 PL 3322724T3
Authority
PL
Poland
Prior art keywords
inhibitors
Prior art date
Application number
PL16739098T
Other languages
English (en)
Inventor
Michel Gilliet
Jeremy DI DOMIZIO
Stephan MELLER
Original Assignee
Centre Hospitalier Universitaire Vaudois (Chuv)
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Universitaire Vaudois (Chuv), Board Of Regents, The University Of Texas System filed Critical Centre Hospitalier Universitaire Vaudois (Chuv)
Publication of PL3322724T3 publication Critical patent/PL3322724T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL16739098T 2015-07-13 2016-07-13 Inhibitory IL-26 PL3322724T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15176537 2015-07-13
PCT/EP2016/066688 WO2017009392A1 (en) 2015-07-13 2016-07-13 Il-26 inhibitors
EP16739098.8A EP3322724B1 (en) 2015-07-13 2016-07-13 Il-26 inhibitors

Publications (1)

Publication Number Publication Date
PL3322724T3 true PL3322724T3 (pl) 2021-07-19

Family

ID=53757992

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16739098T PL3322724T3 (pl) 2015-07-13 2016-07-13 Inhibitory IL-26

Country Status (7)

Country Link
US (1) US10751416B2 (pl)
EP (1) EP3322724B1 (pl)
DK (1) DK3322724T3 (pl)
ES (1) ES2860710T3 (pl)
PL (1) PL3322724T3 (pl)
PT (1) PT3322724T (pl)
WO (1) WO2017009392A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7061750B2 (ja) * 2017-12-01 2022-05-02 学校法人順天堂 抗ヒトｉｌ－２６抗体
EP3784776A4 (en) * 2018-05-23 2022-01-26 National University of Singapore Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies
JPWO2021251340A1 (pl) * 2020-06-08 2021-12-16

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797813B2 (en) * 1996-09-23 2004-09-28 Schering Corporation AK155 antibodies and binding fragments thereof

Also Published As

Publication number Publication date
DK3322724T3 (da) 2021-04-12
EP3322724B1 (en) 2021-01-06
ES2860710T3 (es) 2021-10-05
US10751416B2 (en) 2020-08-25
WO2017009392A1 (en) 2017-01-19
PT3322724T (pt) 2021-04-08
EP3322724A1 (en) 2018-05-23
US20180207271A1 (en) 2018-07-26

Similar Documents

Publication Publication Date Title
IL287113A (en) smyd inhibitors
IL254187A0 (en) beta-tgf inhibitors
IL258159B (en) New proprotein inhibitors
IL246785A0 (en) Benzimidazole-2-amines as midh1 inhibitors
GB201421083D0 (en) Enzyme inhibitors
IL248895A0 (en) Phosphatidylinositol 3-kinase inhibitors
GB201421088D0 (en) New enzyme inhibitors
GB201508950D0 (en) Methods
GB201421085D0 (en) New enzyme inhibitors
ZA201907136B (en) Ip6k inhibitors
IL256427A (en) ido inhibitors
IL265139B (en) Dopamine-b-hydroxylase inhibitors
GB201612860D0 (en) Inhibitors
GB201508927D0 (en) Methods
GB201501004D0 (en) Inhibitors
IL274550A (en) Dopamine-B-hydroxylase inhibitors
PT3322724T (pt) Inibidores da il-26
IL253322A0 (en) bace1 inhibitors
GB201520949D0 (en) Inhibitors
IL247025A0 (en) enzyme inhibitors
EP3067422C0 (en) CT-1 INHIBITORS
GB201401005D0 (en) Inhibitor
GB201721465D0 (en) Inhibitors
GB201720189D0 (en) Dopamine-B-hydroxylase inhibitors
GB201418154D0 (en) Inhibitors